Form 8-K - Current report:
SEC Accession No. 0001326190-25-000031
Filing Date
2025-05-13
Accepted
2025-05-13 07:04:35
Documents
18
Period of Report
2025-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20250513x8k.htm   iXBRL 8-K 53758
2 EX-99.1 alt-20250513xex99d1.htm EX-99.1 139326
3 EX-99.2 alt-20250513xex99d2.htm EX-99.2 16680
4 GRAPHIC alt-20250513xex99d1002.jpg GRAPHIC 7092
5 GRAPHIC alt-20250513xex99d2002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-25-000031.txt   389776

Data Files

Seq Description Document Type Size
6 EX-101.SCH alt-20250513.xsd EX-101.SCH 3270
7 EX-101.LAB alt-20250513_lab.xml EX-101.LAB 18715
8 EX-101.PRE alt-20250513_pre.xml EX-101.PRE 12848
20 EXTRACTED XBRL INSTANCE DOCUMENT alt-20250513x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 25937091
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)